A metabolic clue linking glioblastoma cells susceptibility with an energetic metabolism was provided by Indraccolo and colleagues [87], who demonstrated that the activation of the kinase AMPK correlates with sensitivity to regorafenib. The gene discussed is PRKAA2; the disease is glioblastoma.